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Cells undergoing apoptosis in vivo are rapidly detected and 
cleared by phagocytes. Swift recognition and removal of apoptotic 
cells is important for normal tissue homeostasis and failure in the 
underlying clearance mechanisms has pathological consequences 
associated with inflammatory and auto-immune diseases. Cell 
cultures in vitro usually lack the capacity for removal of non-
viable cells because of the absence of phagocytes and, as such, 
fail to emulate the healthy in vivo micro-environment from 
which dead cells are absent. While a key objective in cell culture 
is to maintain viability at maximal levels, cell death is unavoid-
able and non-viable cells frequently contaminate cultures in 
significant numbers. Here we show that the presence of apoptotic 
cells in monoclonal antibody-producing hybridoma cultures has 
markedly detrimental effects on antibody productivity. Removal 
of apoptotic hybridoma cells by macrophages at the time of 
seeding resulted in 100% improved antibody productivity that 
was, surprisingly to us, most pronounced late on in the cultures. 
Furthermore, we were able to recapitulate this effect using novel 
super-paramagnetic Dead-Cert™ Nanoparticles to remove non-
viable cells simply and effectively at culture seeding. These results 
(1) provide direct evidence that apoptotic cells have a profound 
influence on their non-phagocytic neighbors in culture and 
(2) demonstrate the effectiveness of a simple dead-cell removal 
strategy for improving antibody manufacture in vitro.
Introduction
Cell death occurs normally in all tissues via well-known physio-
logical mechanisms, the most widely studied of which is apoptosis. 
A key feature of apoptosis is its non-phlogistic nature: apoptotic 
cells are rapidly removed by phagocytes in vivo without causing 
inflammatory responses or damage to neighboring cells. Failure in 
this clearance mechanism is linked to pathological events associ-
ated with autoimmune and inflammatory diseases. Although cells 
of several different lineages including fibroblasts, epithelial cells 
and endothelial cells have been shown to be capable of engulfing 
their apoptotic neighbors (reviewed in ref. 1), the best-known 
scavenger of apoptotic cells is the macrophage. This professional 
phagocyte is extremely proficient at seeking out sites of apoptosis, 
using receptors that bind chemoattractants including lysophos-
phatidylcholine1 and fractalkine (CX3CL1)
2 that are released from 
apoptotic cells. Consequently in vivo, wherever apoptosis is visible 
in standard histological sections, apoptotic cells and their remnants 
are invariably associated with macrophages. In keeping with the 
non-phlogistic nature of the apoptosis program, the other class of 
professional phagocytes, the granulocytes (or ‘microphages’ as they 
were originally termed) fail to seek out and engulf apoptotic cells. 
As we have recently demonstrated, this is due at least in part to 
the release from apoptotic cells of mediators, including lactoferrin, 
that inhibit granulocyte recruitment.3
Apoptotic cells impose effects on cells in their immediate 
vicinity. It is well known that they cause responses in phagocytes 
including engulfment (involving plasma membrane mobilisation) 
and anti-inflammatory events, perhaps the best known of which is 
TGF-β1 production.4 Under certain circumstances, apoptosis–in 
line with primary necrosis–leads to pro-inflammatory phagocyte 
responses, for example during progression to the post-apoptotic, 
necrotic (cytolysed) state that regularly occurs in vitro or when 
clearance is inhibited in vivo.5 Responses of phagocytes to apop-
totic cells are not, of necessity, coupled only to phagocytosis since 
additional mechanisms dependent on mere contact between the 
dying cells and phagocytes can promote local anti-inflammatory 
effects, as well as suppression of pro-inflammatory signals. For 
example, switching of activated monocytes from pro-inflammatory 
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remnants. Because it has proved difficult to remove dead cells by 
simple methods that do not themselves lead to loss in viability, 
little is yet known about the effects of cell death in culture on 
viable neighboring cells. Given the known effects of apoptotic 
cells upon neighboring cells in which they come into contact and 
the pathological consequences of dead cells that persist in vivo, it 
seemed likely to us at the onset of this work that the behaviour of 
viable cells in vitro could be modulated by the presence of non-
viable cells. We reasoned that presence of dead cells could impose 
inhibitory effects on viable cells in culture and that depletion of 
non-viable cells—through emulation of the normal homeostatic 
process of dead-cell removal—might ‘release’ viable cells from 
the inhibitory effects of their non-viable counterparts. Here we 
demonstrate that monoclonal antibody-producing hybridoma 
cells can markedly improve in their individual capacity to produce 
antibody following a single round of depletion of dead neighbors, 
either by macrophages or by Dead-CertTM Nanoparticles that 
can function as ‘substitute’ phagocytes that remove dead cells 
in a magnetic field. Remarkably, dead-cell removal at the start 
of cell culture significantly improved antibody production over 
protracted culture periods, suggesting that removal of non-viable 
hybridoma cells can cause programming of viable neighboring 
cells for improved antibody production. The mechanisms by 
which dead-cell removal releases/re-programmes hybridoma cell 
populations to produce higher quantities of antibody remain to 
be elucidated.
Results
Apoptotic cells inhibit antibody production by hybridomas. 
In order to establish whether apoptotic cells are capable of modu-
lating antibody production in hybridoma cell populations, we first 
assessed antibody productivity in hybridoma cultures containing 
variable proportions of apoptotic cells at seeding of a constant 
number of viable cells. Variable proportions of apoptotic cells were 
achieved by spiking a constant number of viable cells with apop-
totic cells from crashed cultures in which all cells had died. We 
sought a correlation between population viability at the onset of 
hybridoma culture and antibody productivity. As shown in Figure 
1, a significant inverse correlation was found between antibody 
production and apoptotic cell number at the onset of short-term 
culture. Thus, in the experiment shown, for every percentage point 
increase in apoptosis at the start of the culture, antibody produc-
tivity by the equivalent number of viable cells (at seeding) fell by 
approximately two percentage points (Figure 1). 
These results suggested that non-viable hybridoma cells exert 
inhibitory effects on their viable neighbors.
Removal of apoptotic cells by macrophages promotes anti-
body production. In order to obtain more direct evidence that 
non-viable hybridoma cells exert inhibitory effects on viable cells 
in the same cultures, we used macrophages as a physiological 
mode of depletion of non-viable cells and compared antibody 
productivity of depleted versus control cultures. As shown in 
Figure 2A, culture of 9e10 hybridoma cells in T flasks for a 
period of three weeks following a single depletion of non-viable 
cells using human monocyte-derived macrophages (improving 
to anti-inflammatory states follows contact with apoptotic neutro-
phils.6 Contact-dependent mechanisms that are independent of 
either soluble factors or phagocytic events have also been shown to 
inhibit pro-inflammatory signalling in macrophages downstream 
of TLR signalling pathways.7 Furthermore, contact with apoptotic 
cells can activate a “kiss and tell” response by phagocytes, a contact-
dependent licensing of macrophages to the anti-inflammatory 
effects of TGF-β1 that could play an important role in limiting the 
extent of the apoptosis-driven anti-inflammatory responses to the 
immediate neighborhood of the dying cell.8 Further intercellular 
signalling mechanisms between apoptotic cells and mononuclear 
phagocytes appear to be involved in creating a microenvironment 
that promotes apoptotic-cell clearance. Apoptotic cells can them-
selves produce anti-inflammatory mediators such as IL-109 and 
TGFβ-1,10 each of which is capable of up-regulating the capacity 
of macrophages to clear apoptotic cells.11,12 Intriguingly, the anti-
inflammatory signalling mechanisms that are activated in cells in 
contact with apoptotic cells occur in a wide range of different cell 
lineages in addition to professional phagocytes, including cells with 
no phagocytic capabilities.13 These observations provide strong 
evidence that dying cells have profound effects on the activities of 
cells in their neighborhood.
Local cellular responses to apoptotic cells are not limited to 
those that regulate inflammation and immunity. Although most 
studies to date have focused on the responses of macrophages 
that engulf apoptotic cells, evidence has been presented that 
exposure to apoptotic cells elicits repair responses, including 
growth factor and angiogenic factor production by neighbors.14-16 
Apoptotic cells directly produce factors such as IL-10, TGFβ-1 
and lactoferrin9,10,3 that can affect cell growth and differentia-
tion. Furthermore, the presence of apoptotic cells has been found 
to initiate directional endothelial cell sprouting, an electrostatic 
mechanism resulting from the increased surface negative charge 
of apoptotic cells consequent to redistribution of phospholipids in 
their plasma membranes.17
In addition to releasing chemotactic mediators that allow phago-
cytes to sense them, apoptotic cells also undergo plasma membrane 
changes that are required for intercellular adhesion by phagocytes, 
as well as engulfment and anti-inflammatory responses. The best 
characterised architectural feature of the apoptotic cell surface is 
the loss of phospholipid asymmetry that results in the redistribu-
tion of the anionic phospholipid, phosphatidylserine (PS) from 
the inner plasma membrane leaflet to the outer.18-21 Exposed PS 
can engage with a number of glycoproteins such as MFG-E8 or 
Gas6 that act as bridging molecules to phagocyte receptors such 
as integrins αvβ3/5 or Mer22,23 or directly with integral PS recep-
tors of the phagocyte surface such as TIM-1/4,24-26 BAI127 and 
Stabilin-2.28 Exposure or alteration at the surface of additional 
molecules of various biochemical classes such as sugars, proteins 
and nucleic acid may also be coupled to processes through which 
apoptotic cells condition their microenvironment and interact 
with neighbors and phagocytes.
Although cell culture systems are usually optimized to mini-
mise loss in viability, cells growing in vitro are continuously 
exposed to apoptotic or other forms of non-viable cells and their 
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indicating full recovery of the negatively selected viable cells from 
the input population (Figure 4B).
Removal of apoptotic cells by Dead-Cert™ Nanoparticles 
promotes monoclonal antibody production by hybridoma cells. 
In order to determine whether depletion of non-viable hybridoma 
cells using Dead-Cert™ Nanoparticles could emulate the effects 
of macrophages on antibody productivity as described above, we 
set up hybridoma cultures using untreated (control) or depleted 
(separated using Dead-Cert™ Nanoparticles) hybridoma cells 
(illustrated here using 9e10 but observed also with other hybri-
domas–not shown) at culture seeding and compared antibody 
production levels 3, 7 and 12 days later. As shown in Figure 5 A, 
while similar levels of antibody were produced at 3 days in both 
types of culture, by 12 days, antibody production in the depleted 
cultures was running at almost double that of control cultures. 
When the productivity of antibody per cell was assessed (Figure 
5B), differences in antibody production between control and 
depleted cultures were even more marked, with cells from depleted 
cultures producing more than double the amount of antibody of 
control cultures at 7 and 12 days. Since mere exposure to Dead-
Cert™ Nanoparticles failed to affect cultures (data not shown) 
these results indicate that the enhanced and sustained produc-
tivity of the cultures seeded with depleted cells was due directly 
to the removal of inhibitory non-viable cells by the Dead-Cert™ 
Nanoparticles.
Discussion
Although relatively little is yet known of the underlying 
mechanisms, there is no doubt that non-viable cells condition 
their microenvironment, either directly or via responses of other 
cell types, notably phagocytes. Using two methods to remove 
viability in the experiment illustrated 
from 57 to 96% as assessed by trypan 
blue exclusion), resulted in substan-
tially improved antibody productivity, 
particularly during the later stages of 
culture when antibody productivity 
rose to double that of the untreated 
cells. Similar results were obtained 
using 4/C6 hybridoma cells (data not 
shown).
In order to determine the extent to 
which the improved antibody produc-
tivity observed in depleted cultures 
reflected greater antibody produc-
tion by individual cells, we assessed 
the antibody productivity per cell 
over the course of the culture period. 
As illustrated in Figure 2B, while 
the antibody productivity per cell 
(assessed by dividing the total anti-
body concentration measured at a 
particular time point by the total cell 
count at that time point) was greater 
in the untreated cultures during the 
first week, in depleted cultures the productivity per cell rose 
steadily to reach double that of the untreated cultures by the 
second week, and sustained that level for the remaining week. 
These results suggested that the removal of non-viable cells prior 
to culture set-up enhanced the antibody-producing capacity of 
individual cells during extended culture.
Dead-Cert™ Nanoparticles: new devices for effective removal 
of non-viable cells in vitro. The results obtained above using 
macrophages for depletion of non-viable cells are consistent with 
the conclusion that dead and dying cells exert inhibitory effects on 
antibody production by hybridoma cells. An alternative explanation 
is that the observed effects were induced following ‘activation’ of 
hybridoma cells by macrophage—the latter cells providing signals 
that boost antibody productivity–rather than as a consequence of 
removal of non-viable cells per se. In order to differentiate between 
these two possibilities, we first investigated the utility of Dead-Cert 
Nanoparticles™ in depleting non-viable cells from hybridoma 
cell suspensions as an alternative to macrophages. We have devel-
oped the surface of these 250 nm super-paramagnetic particles to 
discriminate between viable and non-viable cells (Figure 3A) such 
that, following a short incubation step during which the particles 
bind to non-viable cells and sub-cellular debris, viable cells can be 
rescued by negative selection using a simple magnet (Figure 3B). 
We have found this approach to be non-traumatic and effective 
in depletion of non-viable cells of multiple lineages from many 
species (see www.immunosolv.com for further details).
As shown in Figure 4, efficient depletion of non- 
viable hybridoma cells was achieved in a single separation using 
Dead-Cert™ Nanoparticles. In the examples shown, trypan 
blue positive cells were effectively removed using this method 
(Figure 4A and B) and the yield of viable cells was virtually 100% 
Figure 1. Inverse relationship between proportion of non-viable (apoptotic) cells and antibody productivity 
in hybridoma cultures. 2 x 105 viable 4/C6 hybridoma cells/ml were seeded with different proportions of 
apoptotic cells (non-viable cells obtained from cultures at the end of plateau phase). Monoclonal antibody 
(IgG1) productivity was assessed in cell-free supernatants four days later. The inverse correlation was 
significant (p < 0.005)
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improvements in antibody productivity by hybridoma 
cells that were sustained—and indeed increased—with 
time of culture. These improvements were substantial, 
100% or more, suggesting that this strategy has poten-
tial to boost monoclonal antibody manufacturing.
Cell death through apoptosis in cultures of antibody-
producing hybridoma cells is well known,31,32 and 
strategies for improving viability of hybridoma cells 
via suppression of their apoptosis program (such as 
through expression of Bcl-2-family proteins) to improve 
antibody productivity have been widely studied.33,34 
However, to our knowledge, the phenomenon described 
here of substantially improved antibody production by 
hybridoma cells following removal of non-viable cells 
prior to culture seeding has not been reported previ-
ously. The effect is particularly intriguing because it was 
not limited to the initial population of cells from which 
the non-viable cells were removed. Rather, these cells 
appeared, through removal of neighboring non-viable 
cells, to be in some way reprogrammed to produce more 
antibody, and that this reprogramming extended to the 
progeny of the cells that were used to seed the culture. 
Because persistent apoptotic cells have inhibitory effects 
on antibody production by hybridoma cells (as demon-
strated in Figure 1), our interpretation of the apparent 
reprogramming mechanism is that it stems from release 
of viable cells from inhibitory properties of non-viable 
cells.
The nature of the inhibitory components of non-
viable cells awaits definition, but two lines of evidence 
are noteworthy in this context. Firstly, activation of 
inhibitory signalling pathways that suppress pro-inflam-
matory responses by contact with apoptotic cells have 
been reported for multiple cell lineages, including non-
phagocytic cells.13 Second, membranes of killed cells 
have been shown to harbor inhibitory lipid moieties 
capable of suppressing cell growth.35,36 Given the funda-
mental changes in lipid topology of plasma membranes 
that are induced during cell death, the most acclaimed 
of which being the loss of phospholipid asymmetry with 
externalisation of anionic phospholipids such as PS, it 
is tempting to speculate that such externalised compo-
nents act as intercellular signalling structures to mediate 
the inhibitory effects described here. Although PS has 
been identified as a key component of anti-inflam-
matory signalling by phagocytes responding to apoptotic cells,4 
such signalling to other cell types appears to occur independently 
of PS.13 Changes in plasma membrane topology are not limited 
to lipids: intracellular proteins and DNA also become exposed 
at the plasma membrane surface of dying cells, and localised 
alterations in molecular architecture also occur during apoptosis, 
including clustering of key proteins and lipids and alterations 
in surface carbohydrates.4,5 Furthermore, release of molecules 
such as immunomodulators and proteolytic enzymes from dying 
and dead cells provides ample scope for generating wide-ranging 
non-viable cells, (1) macrophages and (2) super-paramagnetic 
particles, we have shown that non-viable hybridoma cells radically 
affect their viable neighbors, and inhibit the antibody-producing 
potential of individual cells. We were able to demonstrate this 
effect in the absence of phagocytes, which provides definitive 
evidence that non-viable hybridoma cells exert direct inhibitory 
effects on viable cells in the same cultures, and that efficient 
removal of non-viable cells can have surprisingly long-lasting 
effects on the remaining viable cells and their progeny. Following a 
single depletion of non-viable cells at culture seeding, we observed 
Figure 2. Antibody production by hybridoma cells after depletion of non-viable cells by 
macrophages. Equal numbers of viable 9e10/4 hybridoma cells (2 x 105 /ml) were 
cultured before (Control, open symbols) or after (Depleted, solid symbols) removal 
of non-viable cells on day 0 using monolayers of HMDM. In the experiment shown, 
viability was improved from 57 to 96% by HMDM-mediated depletion of non-viable 
cells. At the indicated times, cell-free supernatants were assayed for IgG1 content. 
(A) total IgG1 per ml; (B) IgG1 per cell.
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microenvironmental effects. Clearly, there are many candidate 
molecular mechanisms underlying the effects described here and 
substantial future work will be required to elucidate these defini-
tively.
In conclusion, we report a novel negative mechanism control-
ling antibody production by hybridoma cells in vitro that is 
mediated by non-viable neighboring cells. Release from this inhibi-
tory regulation can be readily achieved using an effective procedure 
of removal of non-viable cells using macrophages or, more simply, 
using Dead-Cert™ Nanoparticles at the initiation of culture. This 
procedure has obvious potential in improving antibody manufac-
ture because the removal of non-viable cells can now be achieved 
simply with high yield and efficiency and without trauma to viable 
cells, and can substantially improve antibody productivity not only 
by the remaining viable cells but also by their progeny. Magnetic 
separation technology is amenable to scale-up and Dead-Cert™ 
Nanoparticles have significant potential to improve antibody 
manufacturing at industrial scales.  Furthermore, because of the 
fundamental nature of cell death and the wide ranging 
responses of viable cells to non-viable neighbors, it is likely 
that the inhibitory effects of non-viable cells, as well as the 
release from such inhibitory activities, will prove to extend 
to many different cell systems. The ability to remove non-
viable cells routinely in vitro provides the opportunity to 
enhance cell culture methods by emulating the dead-cell 
removal systems that operate in vivo and also provides a 
critical tool that allows the dissection of the mechanisms 
underlying the inhibitory effects of non-viable cells to 
begin.
Figure 3. Dead-Cert Nanoparticles: simple devices for effective direct 
removal of non-viable cells in vitro. ImmunoSolv’s antibody-based Dead-
Cert technology (see www.immunosolv.com) has been developed to 
discriminate non-viable from viable cells in vitro. ImmunoSolv has used 
antibodies, together with additional discriminatory molecules coupled 
to the surface of 250 nm super-paramagnetic nanoparticles, to develop 
a simple, yet highly effective dead-cell removal device, the Dead-Cert 
Nanoparticle. Because of their ability to bind to membrane structures that 
are not accessible on viable cells–represented by the red symbols in the 
cartoons–the coated particles are able to bind selectively to apoptotic 
(dying) as well as necrotic (dead) cells and cell debris. Once bound to 
non-viable cells and debris, the Dead-Cert Nanoparticles can be readily 
removed with the aid of a simple magnet leaving the ‘untouched’ viable 
cells purified by negative selection.
Figure 4. Depletion of non-viable hybridoma cells using Dead-
Cert Nanoparticles. Hybridoma cells (9e10/18) taken from 
the end of plateau phase of culture were subjected to a single 
magnetic separation using Dead-Cert Nanoparticles. (A) Light 
micrographs of untreated (Control) and separated (Depleted) 
cells exposed to trypan blue to label dead cells. (B) Quantitative 
analyses of untreated and separated cell populations. Cells were 
counted in Neubauer haemocytometer chambers following expo-
sure to trypan blue.
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Materials and Methods
Hybridoma culture. In-house sub-clones of the murine hybri-
doma line, 9e10 (9e10/4) and (9e10/18) that produce IgG1 
monoclonal antibody against c-Myc29 were used for the majority 
of these studies. Additional, and confirmatory experiments were 
performed using a different IgG1-producing hybridoma, 4/
C6, generated in our laboratory. Cells were cultured in RPMI 
1640 medium (InVitrogen) containing 10% (v/v) FCS (PAA 
Laboratories), 2 mM L-glutamine and antibiotics (PAA 
Laboratories). Viability was assessed routinely by microscopic 
analysis of trypan blue-stained (0.2%) cell populations. Cell death 
occurred through apoptosis, as diagnosed using DAPI or acridine 
orange staining as described30 and apoptotic hybridoma cells 
rapidly became permeable to trypan blue.
Assessment of antibody production. IgG1 was measured 
in cell-free supernatants either by single radial immunodif-
fusion using a sheep anti-mouse IgG antiserum and purified 
mouse IgG1 as calibrator, or by sandwich ELISA using goat 
anti-mouse Ig (Sigma) as capture antibody and goat anti-
mouse IgG-peroxidase  conjugate (Sigma)  followed by OPD 
for visualisation (Sigma). The reaction was stopped using 
H2SO4 and absorbances were read at 492 nm using an Anthos 
plate reader.
Removal of non-viable cells using macrophages. 
Prior to culture seeding, 9e10/4 hybridoma cells from 
plateau-phase cultures were subjected to panning on 
monolayers of human monocyte-derived macrophages 
(HMDM) prepared as described.30 Monocytes were culti-
vated for seven days (approximately 107 monocytes per 
25 cm2 tissue culture flask) in Iscove’s modified Dulbecco’s 
medium (IMDM) containing 2 mM L-glutamine and 10% 
autologous serum at 37°C in an atmosphere of 5% CO2 in air. 
Culture medium was replenished every three days. Immediately 
before panning, flasks containing mature HMDM were 
rinsed three times with pre-warmed (37°C) culture medium. 
Hybridoma cells (107 total cells) were subsequently added 
(approximately 20 non-viable cells per macrophage) in 2 ml 
culture medium and incubated for 2 hours at 37°C in 5% 
CO2 in air with gentle rocking every 30 minutes. Hybridoma 
cells which failed to attach to, or be engulfed by, HMDM 
were recovered by decanting culture medium and rinsing the 
monolayer gently with fresh culture medium (10 ml). Cells 
recovered from panning, together with controls, were resus-
pended at 2 x 105 viable cells/ml in 5 ml fresh hybridoma 
culture medium and cultured in 25 cm2 tissue culture T flasks. 
Viability of control and depleted cell preparations was deter-
mined using 0.2% trypan blue.
Removal of non-viable cells using Dead-Cert™ 
Nanoparticles. 9e10/18 hybridoma cell populations were 
depleted of non-viable cells using Dead-CertTM Nanoparticles 
according to the manufacturer’s instructions. Briefly, 5 x 
106 hybridoma cells from plateau-phase cultures were resus-
pended in 200 μl culture medium containing Dead-CertTM 
Nanoparticles (20 μl washed particles from stock). Care was 
taken to resuspend the stock suspension of particles by vortexing 
for at least 30 seconds and gentle pipetting. Cells were incubated 
with Dead-CertTM Nanoparticles upright in a 1.5 ml Eppendorf 
tube at 4°C for 30 minutes. 0.8 ml culture medium was subse-
quently added to the mixture which was thoroughly resuspended 
by aspiration using a 1 ml pipette tip. The tube was then placed 
on a magnet for 3 minutes at ambient temperature and (viable) 
cells remaining in suspension were carefully removed, resuspended 
at 2 x 105 viable cells/ml in fresh hybridoma culture medium 
and cultured in 24-well tissue culture plates. Further details of 
the composition, specificity and application of Dead-Cert™ 
Nanoparticles including laboratory protocols and a video detailing 
the separation process can be obtained at www.immunosolv.com.
Figure 5. Antibody production by hybridoma cells after depletion of non-viable 
cells by Dead-Cert Nanoparticles. Equal numbers of viable 9e10/18 hybri-
doma cells (2 x 105/ml) were cultured before (Control) or after (Depleted) 
removal of non-viable cells on day 0 using Dead-Cert Nanoparticles. In the 
experiment shown, viability was improved from 64% to 95% by Dead-Cert 
Nanoparticle-mediated magnetic depletion of non-viable cells. At the indicated 
times, cell-free supernatants were assayed for IgG1 content. (A) Total IgG1 per 
ml; (B) IgG1 per cell.
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